Title: The Clinical Effects on Type 2 Diabetes' Adjuvant Therapy by Pioglitazone and its Influence on Exogenous Insulin Dosage
Abstract: Objective: To explore the effects of treating type 2 diabetes(T2DM) by subcutaneous insulin injection assisted with pioglitazone and its influence on exogenous insulin dosage. Method: 86 cases with T2DM were randomly divided into group A and B, 43 patients per group. Patients in group A were mainly given insulin therapy, and patients in group B were given adjuvant therapy by pioglitazone based on group A, and two groups were both treated for 8 weeks. Before and after treatment, two groups' blood glucose, HbA1c, insulin resistance index(Homa IR), and were observed in patients with blood glucose, HbA1c, insulin resistance index(Homa IR), the change of exogenous insulin dosage with adverse reactions were observed. Result: After treatment, group A and B's FPG, 2 h PPG, HbA1c and Homa-IR were all improved comparing with before treatment(P0.05), and group B's FPG, 2 h PPG, HbA1c and Homa-IR were all lower than that of group A, also average insulin dosage was lower than group A(P0.05). Group A and B's total effective rate were 76.74% and 93.02% respectively, and the differences between the two groups were statistically significant(P0.05). Group A and B's hypoglycemia reaction rate were 4.65% and 6.98%, and the differences between the two groups were not statistically significant(P0.05). Conclusion: It effectively controls T2DM patients' blood glucose, improves insulin resistance, and reduces insulin dosage, without increase hypoglycemia incidence, also with high security by treating assisted with pioglitazone.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot